Liminatus Pharma Business Summary

Liminatus Pharma, Inc. (LIMN) is a clinical-stage biopharmaceutical company that operates on a research-and-development business model, currently generating no commercial revenue. The company’s primary revenue strategy centers on the future licensing, milestone-based partnerships, and eventual commercialization of its immunotherapy pipeline, which is divided into two main segments: novel checkpoint inhibitors and cancer vaccines. Its lead candidate, IBA101, is a humanized anti-CD47 monoclonal antibody engineered to avoid the severe anemia typical of first-generation blockades, while its Phase II GCC vaccine targets colorectal and gastric cancers. The firm also maintains a diagnostic segment focused on early-stage pancreatic cancer detection through a deep-learning metabolomic platform. Liminatus competes with oncology-focused biotechs such as Sutro Biopharma, Spero Therapeutics, and Oramed Pharmaceuticals, positioning itself as a specialized developer of "next-generation" biologics with superior safety profiles compared to larger incumbents like Kite Pharma. The company is led by CEO and Chairman Chris Kim, whose background includes serving as intellectual property counsel for pharmaceutical leaders such as Merck, Pfizer, and GSK. The executive suite includes CFO Scott Dam, a former Managing Director at Raymond James with deep healthcare investment banking experience, and Chief Science Officer Byong C. Yoo, an expert in biochemistry and proteomics from the National Cancer Center of Korea. Technical operations are managed by CTO Beom Choi and Head of R&D Sang-jin Lee. Liminatus is backed by Arrow Capital through its 2025 business combination with Iris Acquisition Corp and recently secured a $30 million equity financing memorandum from Capital Trust Group. The board of directors features notable industry veterans including Philip Lemons, owner of Nine18 Consulting, and Richard Baek, providing oversight as the firm navigates its clinical milestones and a unique digital asset treasury strategy.